ICT-107 immunocellular Therapeutics Shows 80 percent survival at 2 years in Phase I study of newly diagnosed … LOS ANGELES —- immunocellular Therapeutics, Ltd. a biotechnology company focused on developing new therapies for immune-based cancer, announced today that data from a recent clinical trial of ICT-107 dendritic cells of the company based cancer vaccine candidates for the treatment of glioblastoma multiforme, will be presented at the 46th annual session American Society of Clinical …
Could this be a Cure for All Skin Conditions?